Cantor Fitzgerald set a $5.00 price objective on Genocea Biosciences (NASDAQ:GNCA) in a research note issued to investors on Sunday morning. The firm currently has a buy rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Genocea Biosciences’ FY2018 earnings at ($0.59) EPS and FY2019 earnings at ($0.65) EPS.
“GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities.”,” Cantor Fitzgerald’s analyst wrote.
Several other research analysts have also issued reports on the company. HC Wainwright began coverage on Genocea Biosciences in a research report on Thursday, March 8th. They set a buy rating and a $5.00 target price for the company. Robert W. Baird began coverage on Genocea Biosciences in a research report on Monday, February 12th. They set an outperform rating and a $3.00 target price for the company. Needham & Company LLC upgraded Genocea Biosciences from a hold rating to a buy rating and set a $3.00 target price for the company in a research report on Tuesday, February 6th. Finally, Zacks Investment Research lowered Genocea Biosciences from a buy rating to a hold rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $4.41.
Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. equities research analysts forecast that Genocea Biosciences will post -0.59 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. raised its stake in shares of Genocea Biosciences by 11.5% during the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $159,000. California State Teachers Retirement System bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $265,000. Teachers Advisors LLC bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $268,000. Finally, TIAA CREF Investment Management LLC bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $404,000. 10.29% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This article was originally published by BBNS and is the property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/2018/03/14/genocea-biosciences-gnca-pt-set-at-5-00-by-cantor-fitzgerald/2027881.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.